ArticleCancer immunology, immunotherapy : CII2010
Ten-year survival analysis for renal carcinoma patients treated with an autologous tumour lysate vaccine in an adjuvant setting.
Article in Cancer immunology, immunotherapy : CII, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 46 citations in OpenAlex.
- Autologous tumor cell vaccination combined with systemic CpG-B and IFN-α promotes immune activation and induces clinical responses in patients with metastatic renal cell carcinoma: a phase II trial.Cancer immunology, immunotherapy : CII · 2019Trial
- Risk of autoimmunity, cancer seeding, and adverse events in human trials of whole-tissue autologous therapeutic vaccines.Cancer pathogenesis and therapy · 2025Review
- Tumor-derived granulocyte colony-stimulating factor diminishes efficacy of breast tumor cell vaccines.Breast cancer research : BCR · 2018Article
- Immunotherapy with subcutaneous immunogenic autologous tumor lysate increases murine glioblastoma survival.Scientific reports · 2017Article
- Specific immunotherapy in renal cancer: a systematic review.Therapeutic advances in urology · 2017Review
- Evolving Immunotherapy Approaches for Renal Cell Carcinoma.Current oncology reports · 2016Review
- Tumor heterogeneity as a rationale for a multi-epitope approach in an autologous renal cell cancer tumor vaccine.OncoTargets and therapy · 2016Article
- Autologous tumor lysate/Bacillus Calmette-Guérin immunotherapy as an adjuvant to conventional breast cancer therapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2015Article
- Harnessing the PD-1 pathway in renal cell carcinoma: current evidence and future directions.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2014Review
- Victory and defeat in the induction of a therapeutic response through vaccine therapy for human and canine brain tumors: a review of the state of the art.Critical reviews in immunology · 2014Review
- Denatured mammalian protein mixtures exhibit unusually high solubility in nucleic acid-free pure water.PloS one · 2014Article
- A pilot study of autologous tumor lysate-loaded dendritic cell vaccination combined with sunitinib for metastatic renal cell carcinoma.Journal for immunotherapy of cancer · 2014Article
- Increasing the efficacy of tumor cell vaccines by enhancing cross priming.Cancer letters · 2012Review
- Selected anti-tumor vaccines merit a place in multimodal tumor therapies.Frontiers in oncology · 2012Article
- Therapeutic vaccines in renal cell carcinoma.Therapy (London, England : 2004) · 2011Article
- [Renal cell carcinoma: recent developments in diagnostics and therapy].Der Urologe. Ausg. A · 2010Article
- Focus on kidney cancer: Significant overall survival advantage for RCC patients treated with autologous tumor lysate vaccine.Nature reviews. Urology · 2010Article
- Immunotherapy. Significant overall survival advantage for RCC patients treated with autologous tumor lysate vaccine.Nature reviews. Clinical oncology · 2010Article
- Immunologic mechanisms in RCC and allogeneic renal transplant rejection.Nature reviews. Urology · 2010Review
- Recent updates in renal cell carcinoma.Current opinion in oncology · 2010Review
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
About 30% of renal cell carcinomas (RCC) will develop recurrence after surgery. Despite evidence for a significantly improved survival by autologous tumour cell vaccination therapy, the procedure has not become standard. Between August 1993 and December 1996, 1,267 RCC patients undergoing radical nephrectomy in 84 German hospitals were subsequently treated by autologous tumour cell vaccination therapy. The study group comprised 692 patients with complete follow-up (stages pT2-3, pNx-2, M0 based on the TNM classification, 4th edition). Subsequent propensity-score matching according to 7 defined criteria with 861 control patients undergoing nephrectomy alone without adjuvant treatment at the Carl-Thiem-Hospital Cottbus, resulted in 495 matched pairs. Overall and stage-specific survival rates were analysed after a median follow-up of 131 months. The 5- and 10-year overall survival (OS) rates were 80.6 and 68.9% in the vaccine group and 79.2 and 62.1% in the control group (p = 0.066). Patients with pT3 stage RCC revealed 5- and 10-year OS rates of 71.3 and 53.6% in the study group and 65.4 and 36.2% in the control group (p = 0.022). In multivariable analysis, patients in the vaccine group showed a significantly improved survival both in the whole study group (HR = 1.28, p = 0.030) and in the subgroup presenting with pT3 stage tumours (HR = 1.67, p = 0.011). Adjuvant treatment with autologous vaccination therapy resulted in a significantly improved overall survival in pT3 stage RCC patients, suggesting benefit especially in this subgroup. However, controlled clinical trials integrating the recent TNM classification and further risk constellations are required to define additional patient groups that may derive benefit from this treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.